Asia-Pacific Clinical Biomarkers Market Research 2023-2033: Market Growth Fuelled by Advances in Biotechnology and Personalized Medicine

Research and Markets

3 July 2024 at 5:38 am·3-min read

Company Logo

Asia-Pacific Clinical Biomarkers Market

Dublin, July 03, 2024 (GLOBE NEWSWIRE) -- The "Asia-Pacific Clinical Biomarkers Market - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

The Asia-Pacific clinical biomarkers market was valued at $3.28 billion in 2023 and is expected to reach $7.95 billion by 2033, growing at a CAGR of 9.27% between 2023 and 2033. Clinical biomarkers are quantifiable biological parameters that aid in understanding the progression and early diagnosis of diseases. These biomarkers, particularly molecular ones, offer new targets for characterizing diseases and for drug discovery and development.

The Asia-Pacific (APAC) clinical biomarkers market is rapidly expanding, driven by advancements in biotechnology, increased healthcare spending, and a growing focus on personalized medicine. Countries like China, Japan, and India are at the forefront, with substantial investments in research and development and robust clinical trial activities.

The rising prevalence of chronic diseases, such as cancer and cardiovascular conditions, fuels the demand for early diagnostic tools and targeted therapies. Government initiatives and collaborations between academic institutions and biopharmaceutical companies further propel market growth. The integration of advanced technologies, such as next-generation sequencing and bioinformatics, enhances the identification and validation of novel biomarkers, making the APAC region a crucial player in the clinical biomarkers landscape.

How Can This Report Add Value to an Organization?

Growth/Marketing Strategy: Product launches and upgradations accounted for the maximum number of key developments. Numerous synergistic activities, fundings, and acquisitions of the market have also been tracked during the same time period.

Competitive Strategy: The clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Asia-Pacific clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Key Attributes:

Report Attribute	Details
No. of Pages	53
Forecast Period	2023 - 2033
Estimated Market Value (USD) in 2023	$3.28 Billion
Forecasted Market Value (USD) by 2033	$7.95 Billion
Compound Annual Growth Rate	9.2%
Regions Covered	Asia Pacific

Key Topics Covered:

Executive Summary

1 Market

2 Market Scope
2.1 Key Questions Answered in the Report

3 Research Methodology
3.1 Data Sources
3.1.1 Primary Data Source
3.1.2 Secondary Data Sources
3.1.2.1 Open Sources
3.2 Market Estimation Model
3.3 Criteria for Company Profiling

4 Market Overview
4.1 Introduction
4.2 Clinical Biomarkers Approaches in Precision Medicine
4.3 Market Size Potential for Clinical Biomarkers, 2022-2033
4.4 COVID-19 Impact on Clinical Biomarkers Market
4.4.1 COVID-19 Impact on Market Size
4.5 Market Trends
4.5.1 Integration of Artificial Intelligence in Biomarker Discovery
4.5.2 Increasing Biomarkers Usage in Precision Medicine
4.5.3 Technologies Being Used in Clinical Biomarker Testing
4.5.4 Clinical Biomarker Discovery Making Early Disease Diagnosis Possible

5 Region
5.1 Overview
5.2 Asia-Pacific
5.2.1 China
5.2.2 India
5.2.3 Japan
5.2.4 South Korea
5.2.5 Australia
5.2.6 Rest-of-Asia-Pacific

6 Market - Company Profiles
6.1 Overview
6.2 BGI
6.2.1 Company Overview
6.2.2 Role of BGI in the Clinical Biomarkers Market
6.2.3 Corporate Strategies
6.2.3.1 Product Launch
6.2.4 Analyst's Perspective
6.3 Novogene Co., Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/pen75w

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

Asia-Pacific Clinical Biomarkers Market

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

The Northern Echo
Popular pub shuts suddenly citing 'problems and other projects' amidst wages row
Disgruntled employees of a popular pub have claimed that wages are still unpaid after the venue unexpectedly shut up shop last month.
Fool.co.uk
I think this is the best dividend stock to buy in the FTSE 250. And it’s dirt cheap!
This FTSE 250 stock isn't just a leader in its space. Our writer thinks it's also a passive income powerhouse trading at a bargain price. But for how long? The post I think this is the best dividend stock to buy in the FTSE 250. And it’s dirt cheap! appeared first on The Motley Fool UK.
The Telegraph
What Labour has in store for your pension
The pensioner vote has been a key battleground in this election. One of the Conservatives’ key pledges was the introduction of the “triple lock plus”, a higher tax-free personal allowance for the retired.
Fool.co.uk
1 UK artificial intelligence (AI) stock to consider buying while it’s down 61%
Our writer shines a light on one fascinating UK stock operating in the semiconductor space that's tipped for explosive growth. The post 1 UK artificial intelligence (AI) stock to consider buying while it’s down 61% appeared first on The Motley Fool UK.
Bradford Telegraph and Argus
Shop boss fined thousands for not complying with enforcement notice from 14 years ago
THE owner of a Conservation Area business has been ordered to pay over £8,000 for failing to comply with an enforcement notice issued almost 14 years ago.
The Telegraph
Questor: This stock is poised to profit from Britain’s economic recovery
Many investors have concluded that the UK economy is a basket case, but the reality is very different.
Fool.co.uk
2 exciting growth stocks I’m looking to buy and hold for a decade!
Sumayya Mansoor breaks down why these two growth stocks look like no-brainer buys for her holdings to offer excellent growth and returns. The post 2 exciting growth stocks I’m looking to buy and hold for a decade! appeared first on The Motley Fool UK.
Reuters Videos
Jeff Bezos sells $5 bln Amazon shares as stock soars
STORY: Jeff Bezos is cashing in. The Amazon founder and executive chair is selling stock in the company worth almost $5 billion. His proposed sale was revealed in a regulatory filing. The move comes after the shares hit record highs. Amazon stock this week passed $200, up more than 30% so far this year.That far outpaces the 4% gain for the Dow Jones index. The e-commerce titan posted upbeat results in April, boosted by investments in AI. After the sale plan, Bezos would still have about 912 million Amazon shares - or close to 9% of the outstanding stock. He sold shares worth some $8.5 billion in February, after the stock rallied 80% last year. Bezos is the second-richest person in the world, with a net worth of over $214 billion. That’s according to a tally by Forbes.
The Telegraph
Executive called ‘old fossil’ by younger boss wins £3.1m age discrimination payout
A senior executive at a FTSE 250 firm who was told by his younger boss he was an “old fossil” who “did not know how to manage millennials” has won a £3.1 million age discrimination payout.
Associated Press Finance
Parent company of Saks Fifth Avenue to buy Neiman Marcus for $2.65 billion
The parent company of Saks Fifth Avenue has signed a deal to buy upscale rival Neiman Marcus Group, which owns Neiman Marcus and Bergdorf Goodman stores, for $2.65 billion, with online behemoth Amazon holding a minority stake. The new entity will be called Saks Global, creating a luxury powerhouse at a time when the arena has become increasingly fragmented with different players, from online marketplaces that sell luxury goods to upscale fashion and accessories brands opening up their own stores.
Fool.co.uk
Down 20% in a month, is this the biggest bargain in the FTSE 250?
Jon Smith explains why a FTSE 250 stock has been dropping in value recently, but why he believes it could rally in the future. The post Down 20% in a month, is this the biggest bargain in the FTSE 250? appeared first on The Motley Fool UK.
The Telegraph
Buy British, banks tell stock traders ahead of predicted Labour landslide
Traders are being urged to buy British stocks and bonds amid predictions of a crushing Labour election victory.
Fool.co.uk
6.6% and 3.9% yields! 2 FTSE 100 stocks I’d snap up for juicy returns
On the hunt for consistent and growing dividends, our writer earmarks these two FTSE 100 stalwarts that could help her achieve that. The post 6.6% and 3.9% yields! 2 FTSE 100 stocks I’d snap up for juicy returns appeared first on The Motley Fool UK.
Fool.co.uk
Buying 11,800 shares of this REIT today unlocks £100 in monthly passive income
Some of the most lucrative income investments are REITs. Here's one from Zaven Boyrazian's portfolio that could generate £100 a month over time. The post Buying 11,800 shares of this REIT today unlocks £100 in monthly passive income appeared first on The Motley Fool UK.
Fortune
Elon Musk’s Tesla recoups all its year-to-date losses after adding a staggering $150bn in market cap in just 3 days: ‘Worst is in the rear view mirror’
Investor faith in Tesla's once busted-growth story appears to have returned after a dire first-half that saw it become the butt of jokes.
Reuters
BYD's steep EV discounting in Thailand sparks backlash, PM seeks assurances
Thailand's consumer protection agency has received about 70 complaints since initiating a probe into aggressive discounting by BYD dealers that has left some buyers feeling they overpaid for their Chinese electric vehicles. Prime Minister Srettha Thavisin told BYD Chief Executive Wang Chuanfu, who was in Thailand to mark the opening of its first Southeast Asian factory this week and paid a courtesy call to the premier on Friday, to better manage customer expectations about pricing and ensure local buyers were protected. Wang gave assurances that future pricing would be appropriate and affected customers would receive support, according to a government spokesman.
AFP
EU slaps Chinese electric cars with tariffs of up to 38%
The European Union on Thursday slapped extra provisional duties of up to 38 percent on Chinese electric car imports because of Beijing's "unfair" support, a move that risks escalating tensions with Beijing.- Expected cut to imports - The United States has already hiked customs duties on Chinese electric cars to 100 percent, while Canada is considering similar action.
The Guardian
British electricity prices could hinder switch to green technology, says steel industry
UK Steel says British firms paid prices in spring well over double French and Spanish equivalents
Reuters
Analysis-China, struggling to make use of a boom in energy storage, calls for even more
BEIJING (Reuters) -Rows of what look like thin, white shipping containers are lined up on a barren dirt field in China's Shandong province. Filled with batteries, they form a 795 megawatt (MW) plant that can hold up to 1 million kilowatt-hours of electricity - enough to power 150,000 households for a day, making it China's largest such storage facility when it was connected to the grid last Saturday. Built by Lijin County Jinhui New Energy Co, the project is part of an explosion in development of energy storage in China, which has called for even more investment in the sector to boost renewable electricity and ease grid bottlenecks.
EADT
4,000 unsafe items set for eBay seized by Suffolk Trading Standards
Suffolk Trading Standards has seized thousands of unsafe products set to be sold on eBay.

FTSE 100

FTSE 250

AIM

GBP/EUR

GBP/USD

Bitcoin GBP

CMC Crypto 200

S&P 500

DOW

CRUDE OIL

GOLD FUTURES

NIKKEI 225

HANG SENG

DAX

CAC 40

What the new Labour government means for your money

Asia-Pacific Clinical Biomarkers Market Research 2023-2033: Market Growth Fuelled by Advances in Biotechnology and Personalized Medicine

Latest stories

Popular pub shuts suddenly citing 'problems and other projects' amidst wages row

I think this is the best dividend stock to buy in the FTSE 250. And it’s dirt cheap!

What Labour has in store for your pension

1 UK artificial intelligence (AI) stock to consider buying while it’s down 61%

Shop boss fined thousands for not complying with enforcement notice from 14 years ago

Questor: This stock is poised to profit from Britain’s economic recovery

2 exciting growth stocks I’m looking to buy and hold for a decade!

Jeff Bezos sells $5 bln Amazon shares as stock soars

Executive called ‘old fossil’ by younger boss wins £3.1m age discrimination payout

Parent company of Saks Fifth Avenue to buy Neiman Marcus for $2.65 billion

Down 20% in a month, is this the biggest bargain in the FTSE 250?

Buy British, banks tell stock traders ahead of predicted Labour landslide

6.6% and 3.9% yields! 2 FTSE 100 stocks I’d snap up for juicy returns

Buying 11,800 shares of this REIT today unlocks £100 in monthly passive income

Elon Musk’s Tesla recoups all its year-to-date losses after adding a staggering $150bn in market cap in just 3 days: ‘Worst is in the rear view mirror’

BYD's steep EV discounting in Thailand sparks backlash, PM seeks assurances

EU slaps Chinese electric cars with tariffs of up to 38%

British electricity prices could hinder switch to green technology, says steel industry

Analysis-China, struggling to make use of a boom in energy storage, calls for even more

4,000 unsafe items set for eBay seized by Suffolk Trading Standards